| The competing endogenous RNA network of CYP 4Z1 and pseudogene CYP 4Z2P exerts an anti‐apoptotic function in breast cancer C Li, L Zheng, Y Xin, Z Tan, Y Zhang, X Meng, Z Wang, T Xi FEBS letters 591 (7), 991-1000, 2017 | 30 | 2017 |
| Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease Z Wang, B Verstockt, J Sabino, S Vermeire, M Ferrante, P Declerck, ... British Journal of Clinical Pharmacology 88 (1), 323-335, 2022 | 15 | 2022 |
| Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases W Kantasiripitak, A Outtier, SG Wicha, A Kensert, Z Wang, J Sabino, ... CPT: Pharmacometrics & Systems Pharmacology 11 (8), 1045-1059, 2022 | 13 | 2022 |
| Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues Z Wang, E Dreesen Current Opinion in Pharmacology 55, 53-59, 2020 | 13 | 2020 |
| Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases W Kantasiripitak, Z Wang, I Spriet, M Ferrante, E Dreesen Expert review of clinical pharmacology, 2021 | 12 | 2021 |
| Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a simulation study Z Wang, B Verstockt, J Sabino, M Ferrante, S Vermeire, E Dreesen Clinical Gastroenterology and Hepatology 21 (12), 3188-3190. e2, 2023 | 7 | 2023 |
| Model-informed precision dosing during infliximab induction therapy reduces variability in exposure and endoscopic improvement between patients with ulcerative colitis R Faelens, Z Wang, T Bouillon, P Declerck, M Ferrante, S Vermeire, ... Pharmaceutics 13 (10), 1623, 2021 | 6 | 2021 |
| Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis R Soenen, Z Wang, L Grine, E Dreesen, L Schots, E Brouwers, P Declerck, ... Clinical and Experimental Dermatology 47 (7), 1324-1336, 2022 | 4 | 2022 |
| Therapeutic drug monitoring 2.0: Time to assemble the puzzle Z Wang, E Dreesen Inflammatory Bowel Diseases 30 (2), 316-317, 2024 | 2 | 2024 |
| Exposure–response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis R Soenen, L Schots, Z Wang, L Tilleman, F Van Nieuwerburgh, L Grine, ... Journal of the European Academy of Dermatology and Venereology, 2024 | | 2024 |
| INFLIXIMAB AND PREVENTION OF COLECTOMY IN ACUTE SEVERE ULCERATIVE COLITIS: AN INDIVIDUAL PATIENT DATA META-ANALYSIS Z Wang, W Afif, J Hanzel, T Kobayashi, K Papamichail, X Roblin, ... Gastroenterology 164 (6), S1112-S1113, 2023 | | 2023 |
| Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology D Alsoud, DJAR Moes, Z Wang, R Soenen, Z Layegh, M Barclay, ... Therapeutic Drug Monitoring, 10.1097, 2022 | | 2022 |
| The PPP2R1A hotspot mutant p. R183W promotes anchorage independent growth and predicts therapy response in a type II serous endometrial cancer cell line M Remmerie, Z Wang, M Ohlmeyer, E Dreesen, V Janssens LKI Oncoforum 2022, Date: 2022/05/31-2022/05/31, Location: Leuven, Belgium, 2022 | | 2022 |
| DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease Z Wang, W Kantasiripitak, B Verstockt, S Joao, M Ferrante, P Declerck, ... Journal of Crohn's and Colitis 16 (Supplement_1), i131-i132, 2022 | | 2022 |
| P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn’s disease Z Wang, B Verstockt, S Vermeire, J Sabino, M Ferrante, P Declerck, ... Journal of Crohn's and Colitis 15 (Supplement_1), S335-S336, 2021 | | 2021 |
| MODEL-BASED IDENTIFICATION OF AN OPTIMIZED USTEKINUMAB DOSAGE REGIMEN FOR PATIENTS WITH CROHN'S DISEASE Z Wang, B Verstockt, J Sabino, S Vermeire, M Ferrante, P Declerck, ... Gastroenterology 160 (6), S687-S687, 2021 | | 2021 |
| A Pharmacokinetic-Pharmacodynamic model built on in vitro data predicts the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo Z Wang, C Zhao, S van den Berg, J Mouton, EI Nielsen, LE Friberg | | 2019 |
| Modeling of The Relationship Between Ustekinumab Exposure, Fecal Calprotectin and Endoscopic Outcomes in Patients with C hn Di ea e Z Wang, B Verstockt, J Sabino, S Vermeire, M Ferrante, P Declerck, ... | | |
Erwin Dreesen, MSc, PharmD, PhDKU LeuvenVerified email at kuleuven.be
